Oppenheimer has launched its coverage of BridgeBio Pharma (NASDAQ:BBIO) with a Perform recommendation, noting "substantial challenges" to the company as it races to market its late-stage assets, ...

Much of Josie’s confidence in navigating adolescence as a little person is thanks to her involvement with Little People of ...

Josie Tang Tsz-kwan was born with achondroplasia, the most common form of short-limbed dwarfism. People with this condition ...

A Dalmatian called Dino has become a viral sensation on social media for his small stuature. The dog has dwarfism condition, ...

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

Bhavya Johari will receive these gold medals at the NALSAR's 21st annual convocation from the President Droupadi Murmu ...

(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...

The Beijing government announced plans for a whitelist to expedite the import of orphan drugs approved overseas but not yet ...

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), Wednesday announced positive data from the CANOPY clinical program evaluating Voxzogo in children with achondroplasia, a rare genetic skeletal ...

Predictably, weekly vs. daily subcutaneous injections made a big difference in the achondroplasia space, where shares of Copenhagen, Denmark-based Ascendis Pharma A/S (NASDAQ:ASND) closed Sept. 16 at ...

Last week, Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with ...

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.